Market news

WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement. The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including th

Gainers Exicure (NASDAQ:XCUR) stock rose 38.4% to $2.38 during Tuesday's after-market session. The market value of their outstanding shares is at $10.5 million. Catheter Precision (AMEX:VTAK) stock moved upwards